Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
Date:3/25/2009

SHANGHAI, March 25 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for fourth-quarter and full-year 2008.

    (Logo:http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

    Highlights
    -- Total Company(1) Full-Year 2008 Net Revenues of $261.8 Million
       (Including $8.3 Million of Net Revenues from Discontinued Operations)
       and Adjusted EBITDA of $72.2 Million Achieve Company's Financial
       Guidance
    -- 74% Year-Over-Year Net Revenue Growth from Continuing Operations in
       Fourth Quarter of 2008, 33% Organic Net Revenue Growth for China-Based
       Businesses
    -- 87% Year-Over-Year Net Revenue Growth from Continuing Operations for
       Full-Year 2008, 45% Organic Net Revenue Growth for China-Based
       Businesses
    -- Fourth-Quarter and Full-Year 2008 Net Losses Reflect Non-Cash
       Impairment Charges Relating to Continuing and Discontinued AppTec
       Operations
    -- Construction Completed at Suzhou Toxicology Laboratory and Expanded
       Jinshan Manufacturing Plant
    -- Company Targets 2009 Net Revenues of $265-$275 Million, Including
       15-20% Net Revenue Growth in China-Based Laboratory Services
    -- Key 2009 Investments in Laboratory Services, Toxicology, and
       Manufacturing Services Expected to Drive Revenue Growth in 2010 and
       Beyond

Management Comment

"2008 was a year of extraordinary economic challenges, both in the worldwide economy and the healthcare industry," said Dr. Ge Li, Chairman and Chief Executive Of
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
2. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
3. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
4. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
5. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
6. Pharmatech 2.0: Introducing Pharmatech Oncology
7. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
8. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
9. WuXi PharmaTech Announces Third Quarter 2008 Results
10. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
11. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 28, 2014 The American Association ... University’s School of Nursing with a very prestigious ... program. The 2014 Innovations in Professional Nursing Education ... schools and supports them as they re-envision traditional ... at AACN’s annual meeting in Washington, D.C. to ...
(Date:11/27/2014)... Research and Markets  has announced the ... 2014" report to their offering. ... Acid Industry Report 2014 is a professional and in-depth ... acid industry. The report provides a basic ... industry chain structure. The palmitic acid market analysis is ...
(Date:11/27/2014)... -- Calcivis, a medical devices company ... today announces that it has completed a first ... System. The Calcivis Caries Activity Imaging ... combination designed to transform the assessment and management ... unique, proprietary bioluminescence approach combined with a specialised ...
(Date:11/26/2014)... 26, 2014 The report on the ... segments the concerned market for revenue forecasts and market ... CAGR of 51.9% from 2013 to 2018. At the ... value of $1,415.6 million by 2018. , Browse through ... TOC for information about the market segmentation and in-depth ...
Breaking Biology Technology:American Association of Colleges of Nursing honors Fairfield University’s School of Nursing for Re-envisioning Nursing Education 2Global Palmitic Acid Industry Report 2014 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4
... VIENNA, Austria, November 28 f-star, an antibody,engineering company ... Modular Antibody Technology, today announced that it,has raised EUR ... of its Series,A financing round, originally co-led by Aescap ... raised in the Series A round,increases to EUR 9.0 ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
... November 28 The results of a,study on ... desensitisation product, which is due to receive German ... VO52.06, which was carried out on 280,patients in ... the main evaluation criterion by,demonstrating a statistically significant ...
Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... (March 18, 2009) As any parent knows, children ... University of Washington and the Monell Center indicates that ... and is related to children,s high growth rate. ... sense because when growth is rapid, caloric demands increase. ...
... Mrs. Bruce Reid recorded seeing both a male and ... 1938, Oscar McKinley Bryans observed a ruby-throated hummingbird in ... apple trees were blooming. These are just two of ... on notecards in government files. The cards record more ...
... 2009 Dr. Daniel Von Hoff, Physician-In-Chief of the ... recognizing his achievements in cancer research. Dr. Von ... Clinical Research Services at Scottsdale Healthcare, will be recognized ... special report this month in Arizona Business Magazine. ...
Cached Biology News:Liking sweets makes sense for kids 2It's for the birds 2It's for the birds 3TGen's Dr. Von Hoff wins award for cancer research 2
Human PDGF R beta MAb (Clone # PR7212)...
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: